Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in ...

Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...

Here are some key strategies you can use to help your teams develop the skills needed to excel as executive-level presenters.

Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an announcement. Clarity Pharmaceuticals Ltd responded to an ASX inquiry regarding the ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) ...

Several dozen people attended a recent presentation on the "Impact of the Data Center Boom on Virginia Communities" sponsored by a newly formed group called Winchester-area Interfaith ...